Lipoprotein (a): an emerging risk factor for atherosclerosis.

Lipoprotein (a): an emerging risk factor for atherosclerosis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Lipoprotein (a): an emerging risk factor for atherosclerosis. Abstract Text:

R A Hegele,

Lipoprotein (a) is an antigenic variant of low density lipoprotein and is present in the plasma of most people. Many epidemiologic studies from Europe and North America have found that when plasma levels of lipoprotein (a) exceed 0.20 g/L, there is a significantly higher risk of coronary and cerebrovascular atherosclerosis. Until recently, there has been little insight into the function of lipoprotein (a) or its potential atherogenic mechanism. Molecular biological studies have shown that the characteristic protein of lipoprotein (a), called apolipoprotein (a), strongly resembles plasminogen, the precursor of the natural anticoagulant plasmin. Furthermore, there is emerging evidence that lipoprotein (a) is the missing link between the lipoprotein and coagulation systems, acting perhaps as a vehicle which delivers cholesterol to the site of intravascular damage, or as an inhibitor of plasminogen activation at the site of an evolving thrombus.

Lipoprotein (a): an emerging risk factor for atherosclerosis. Publishing Authors By Initials

RA Hegele,

For similar investigative techniques: epidemiologic methods: statistics as topic: probability: risk: risk factors research abstracts see: investigative techniques: epidemiologic methods: statistics as topic: probability: risk: risk factors research

PUBMED ID PMID:

MEDLINE DATE:

Lipoprotein (a): an emerging risk factor for atherosclerosis. Journal Published:

PUBLICATION TYPE: Review

Journal: The Canadian journal of cardiology

VOLUME: 5

Page Numbers: 263-5

Journal Abbreviation:

ISSN: 1916-7075

DAY: 3

MONTH: 04

YEAR: 2008

Lipoprotein (a): an emerging risk factor for atherosclerosis. Information

Number of References: 23

LANGUAGE: eng

NlmUniqueID: 8510280

Lipoprotein (a): an emerging risk factor for atherosclerosis. Keywords Mesh Terms:

KEYWORDS: Risk Factors

MESH TERMS: physiology

Chemical & Substance for Abstract: Lipoprotein (a): an emerging risk factor for atherosclerosis. Information

Substance Name: Lipoproteins

Registry Number: 0

Grant and Affiliation Information for Lipoprotein (a): an emerging risk factor for atherosclerosis.

AFFILIATION: Howard Hughes Medical Institute, University of Utah, Salt Lake City.

Country: CANADA

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Can J Cardiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Lipoprotein a: an emerging risk factor for atherosclerosis Related Publications

• A Glimpse at HDL-based Therapy for Atherosclerosis.
• Abetalipoproteinemia: two case reports and literature review.
• Adaptation to visuomotor rotations in younger and older adults.
• Association between the -455T>C promoter polymorphism of the APOC3 gene and the metabolic syndrome in a multi-ethnic sample.
• Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample.
• Clinical and genetic associations with hypertriglyceridemic waist in a Canadian aboriginal population.
• Common variants APOC3, APOA5, APOE and PON1 are associated with variation in plasma lipoprotein traits in Greenlanders.
• Effect of change in posture and exercise on repolarization in patients with long QT syndrome with HERG channel mutations.
• Efficacy and safety of pioglitazone in treatment of a patient with an atypical partial lipodystrophy syndrome.
• Emerging antidyslipidemic drugs.
• GCK and HNF1A mutations in Canadian families with maturity onset diabetes of the young (MODY).
• Gene-environment interactions in atherosclerosis.
• Gene-environment interactions in atherosclerosis: animal models.
• Genetic determinants of plasma lipoproteins.
• Genetics of metabolic syndrome.
• Genetics of metabolic syndrome: is there a role for phenomics?
• HIV-associated dyslipidaemia: pathogenesis and treatment.
• Heterozygous CAV1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia.
• Human hepatocyte nuclear factor-1 beta (HNF1B) 1968A/G polymorphism.
• Is raising HDL a futile strategy for atheroprotection?
• Lipoprotein (a): an emerging risk factor for atherosclerosis.
• Lipoprotein(a) and apolipoproteins B and A-I after acute myocardial infarction.
• Lipoprotein(a) and fibrinolysis.
• Lipoprotein(a): biochemistry and genetics.
• Microsomal triglyceride transfer protein inhibition-friend or foe?
• Monogenic pediatric dyslipidemias: Classification, genetics and clinical spectrum.
• Phenomics, lamin A/C, and metabolic disease.
• Single nucleotide polymorphisms of the fukutin gene.
• Spectrum of HNF1A and GCK mutations in Canadian families with maturity-onset diabetes of the young (MODY).
• The failure of torcetrapib: what have we learned?